Tenofovir disoproxil fumarate (ie, tenofovir DF)

Tablet

150mg
200mg
250mg
300mg

Powder, oral

40mg/g of powder (ie, 1 scoopful)

HIV Infection

Indicated in combination with other antiretroviral agents for treatment of HIV-1 infection
300 mg PO qDay

Also available combined with emtricitabine (Truvada), emtricitabine/efavirenz (Atripla), emtricitabine/rilpivirine (Complera)

Hepatitis B Infection

Indicated for chronic hepatitis B
300 mg PO qDay

Renal Impairment

CrCl ≥50 mL/min: No dosage adjustment necessary
CrCl 30-49 mL/min: 300 mg PO q48hr
CrCl 10-29 mL/min: 300 mg PO q72-96hr
CrCl <10 mL/min: Not studied

Hemodialysis: 300 mg PO q7Days or after a total of ~12hr of dialysis

Hepatitis B Transmission (Orphan)

Orphan designation for prevention of mother-to-child transmission of hepatitis B virus
Sponsor

Gilead Sciences, Inc; 333 Lakeside Drive; Foster City, California 94404

Dosing Considerations

Before starting treatment, test for HBV and HIV-1 infection
Assess serum creatinine, estimated CrCl, urine glucose and urine protein in all patients
In patients with chronic kidney disease, also assess serum phosphorus